A Phase 2 study (UX007G-CL-201) is currently ongoing to assess safety and efficacy of UX007 in reducing the frequency of seizures in Glut 1 DS patients. ISTs and other treatment programs are also evaluating UX007 as a treatment for Glut 1 DS.